Amgen (AMGN) Tops Q4 EPS by 42c

Amgen (NASDAQ: AMGN) reported Q4 EPS of $3.81, $0.42 better than the analyst estimate of $3.39. Revenue for the quarter came in at $6.6 billion versus the consensus estimate of $6.58 billion.

GUIDANCE:

Amgen sees FY2021 EPS of $16.00-$17.00, versus the consensus of $17.02. Amgen sees FY2021 revenue of $25.8-26.6 billion, versus the consensus of $26.43 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• XP Inc. (XP) Tops Q2 EPS by 8c
• Yalla Group Limited (YALA) Reports Q2 EPS of $0.24